Skip to main content
. 2018 Jul 30;7(12):e1474318. doi: 10.1080/2162402X.2018.1474318

Figure 3.

Figure 3.

After completion of DC/mCTX-based immunotherapy, all Treg and other T cell populations were returned to baseline levels, the percentage of proliferating CM CD8 T was increased compared to baseline. To determine the effects of DC/mCTX-based immunotherapy, flowcytometric analysis of PBMCs obtained at t = 0 (baseline) and t = 8 (after completing DC/mCTX-based immunotherapy) were compared. To determine IFN·-production, T cells were stimulated 4hrs with PMA/ionomycin in the presence of monensin. A. The proportion of CD3 (41.14%±5.80 vs 39.24%±5.332), CD4 (40.99%±6.81 vs 34.23%±5.38) and CD8 (54.73%±6.91 vs 60.82%±5.67) T cells after DC/mCTX-based immunotherapy were comparable to baseline. B. The percentages of nTregs (1.97%±0.40 vs 1.60%±0.32) and aTregs (3.23%±0.87 vs 3.92%±0.89) did not change significantly. C. The percentages of naïve (28.12%±6.43 vs 20.24%±4.34), CM (15.27%±2.41 vs 13.97%±1.80), EM (38.25%±5.40 vs 45.68%±4010), TEMRA (6.38%±0.85 vs 8.82%±1.53) and activated (6.60%±1.58 vs 5.78%±1.21) CD4 T cells did not change significantly D. Neither did the different subsets in CD8 T cells; naïve (12.49%±4.41 vs 8.19%±3.17), CM (1.73%±0.57 vs 1.29%±0.44), EM (28.19%±3.83 vs 31.42%±4.55) and TEMRA (57.6%±5.94 to 59.12%±5.93). E. Upon treatment with DC/mCTX-based immunotherapy the percentages of proliferating CD4 T cells did not change in the different subsets; naïve (1.50%±0.34 vs 1.73%±0.48), CM (4.12%±0.67 vs 4.77%±0.58), EM (7.21%±1.14 vs 9.21%±1.39), TEMRA (10.23%±3.75 vs 9.75%±3.06) and activated (11.12%±1.15 vs 12.69%±1.30). Neither did the proportion of proliferating nTregs (5.89%±1.48 vs 7.54%±2.04) and aTregs (33.74%±3.11 vs 35.9%±2.55). In CD8 T cells the proportion of proliferating cells was higher in the CM (4.23%±0.88 vs 7.19%±1.50) subset and there was a trend towards more proliferating TEMRA (3.28%±0.76 to 4.98%±1.29). In the naïve (2.13%±1.15 to 3.07%±1.35) and EM (5.71%±1.30 to 6.93%±1.96) subset the proportion of proliferating cells was equal before and after DC/mCTX-based immunotherapy. F. The proportions of IFN·-producing CD4 (16.99%±3.83 vs 15.69%±3.17) and CD8 (41.17%±6.77 vs 34.39%±7.67) T cells did not change significantly, neither did the percentage of GrB+ CD4 (11.26%±3.55 vs 17.41%±6.37) and CD8 (45.33%±7.25 vs 49.31%±10.11) T cells. Results represent mean ± Standard Error of the Mean (SEM). *p < 0.05 (Wilcoxon matched-pairs signed rank test), differences were considered significant when p < 0.05.